Regular Research ArticlesSertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes
Section snippets
Subjects
Details of the study design have been published.13 Briefly, participants 1) were recruited from five memory disorder clinics in the United States; 2) met criteria for dementia due to AD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,15 criteria; 3) had Mini-Mental State Examination (MMSE)16 scores of 10–26, inclusive; and 4) met criteria for dAD.17, 18 dAD criteria differ from Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-TR15
Demographics and Clinical Variables
One hundred thirty-one patients met eligibility criteria and underwent randomization (sertraline = 67, placebo = 64).14 At study entry participants had a median age of 79 years. Fifty-four percent were women; 67% were non-Hispanic white, 21% African American, and 11% Hispanic/Latino. Participants randomized to sertraline had more years of formal education than those in the placebo group. Baseline MMSE and CSDD scores reflected mild-moderate dementia severity and a moderately depressed group,
DISCUSSION
Sertraline treatment is not associated with long-term improvements in mood outcomes and did not lead to any long-term benefit in nonmood NPSs, function, QoL, or global cognition when dAD criteria were used to specify the presence of depression. Although there was no antidepressant treatment effect, there was significant improvement for the entire study sample in mood, NPSs, and QoL. For instance, 41% of all patients met response criteria and CSDD scores decreased on average by approximately 50%
References (35)
- et al.
A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease
Am J Geriatr Psychiatry
(2000) - et al.
Design of Depression in Alzheimer's Disease Study-2
Am J Geriatr Psychiatry
(2006) - et al.
Provisional diagnostic criteria for depression of Alzheimer disease
Am J Geriatr Psychiatry
(2002) - et al.
Provisional diagnostic criteria for depression in Alzheimer disease: rationale and background
Am J Geriatr Psychiatry
(2002) - et al.
Cornell Scale for depression in dementia
Biol Psychiatry
(1988) - et al.
Acute eosinophilic pneumonia associated to sertraline
Med Clin (Barc)
(2002) - et al.
Observed association between antidepressant use and pneumonia risk was confounded by comorbidity measures
J Clin Epidemiol
(2007) - et al.
Point and 5-year prevalence of neuropsychiatric symptoms in dementia: the Cache County Study
Int J Geriatr Psychiatry
(2007) - et al.
Neuropsychiatric disturbance in Alzheimer disease clusters into three groups: the Cache County study
Int J Geriatr Psychiatry
(2001) - et al.
Carer's burden and depressive symptoms in patients with Alzheimer's disease
Rev Neurol
(2002)
The persistence of neuropsychiatric symptoms in dementia: the Cache County Study
Int J Geriatr Psychiatry
Treatment with antidepressants in patients with dementia–a nationwide register-based study
Int Psychogeriatr
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease
J Neuropsychiatry Clin Neurosci
Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial
Br J Psychiatry
Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS
Arch Gen Psychiatry
Double-blind trial of imipramine in Alzheimer's disease patients with and without depression
Am J Psychiatry
The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study
Br J Psychiatry
Cited by (127)
Putative pathological mechanisms of late-life depression and Alzheimer's disease
2023, Brain ResearchDepression in Alzheimer's Disease: Epidemiology, Mechanisms, and Treatment
2023, Biological PsychiatryNeuropsychiatric Aspects of Alzheimer Dementia: From Mechanism to Treatment
2020, Psychiatric Clinics of North AmericaSertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial
2019, American Journal of Geriatric PsychiatryDepression in neurodegenerative diseases: Common mechanisms and current treatment options
2019, Neuroscience and Biobehavioral Reviews
This work was supported by the National Institute of Mental Health, 1U01MH066136, 1U01MH068014, 1U01MH066174, 1U01MH066175, 1U01MH066176, and 1U01MH066177.
The disclosures given below refer to the period between July 1, 2002, and October 31, 2008, and include any anticipated conflicts through December 31, 2009, according to the Depression of Alzheimer's Disease-2 Conflict of Interest Policy (available on request from the study PI).
Barbara K. Martin is involved in another trial for which Pfizer donated a different drug; Paul B. Rosenberg has received research funds from Pfizer, Elan, Lilly and Merck in amounts greater than $10,000; Jacobo Mintzer has received research support from Abbott to study donepezil and divalproex sodium, from AstraZeneca to study quetiapine, from BMS to study aripiprazole, from Eli Lilly to study olanzapine, from Forest to study both citalopram and memantine, from Janssen to study galantamine and risperidone, and from Pfizer to study donepezil and memantine; Dr. Mintzer also has been a consultant, paid directly or indirectly, for AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer, Forest, and Aventis. He also has been an unpaid consultant for Targacept and has participated in Speaker's Bureaus for Janssen, Forest, and Pfizer; Daniel Weintraub has received research support from Boehringer Ingelheim; Dr. Weintraub also has been a paid consultant for Acadia Pharmaceuticals, Novartis Pharmaceuticals, Boehringer Ingelheim, Osmotica Pharmaceutical, BrainCells Inc., Merck Serono, and Sanofi Aventis, and has participated on a Speaker's Bureau for Pfizer; Anton P. Porsteinsson is involved in research sponsored by Pfizer to study donepezil and PF04494700, Eli Lilly to study atomoxetine, a gamma-secretase inhibitor and a beta amyloid antibody, Wyeth to study a beta amyloid antibody, GSK to study a PPAR-gamma agonist inhibitor and Forest to study memantine and neramexane; Dr. Porsteinsson has been a paid consultant and participated on a Speaker's Bureau for Pfizer and Forest; Lon S. Schneider is involved in research sponsored by Pfizer; Dr. Schneider has been a paid consultant for Forest, GlaxoSmithKline, Lilly, Merck, and Wyeth; Constantine Frangakis has no conflict of interests; Lea T. Drye has no conflict of interests; Peter V. Rabins has participated on Speaker's Bureaus for Wyeth, Eli Lilly, and Pfizer and has received reimbursement for legal testimony from Janssen Pharmaceutica. Cynthia A. Munro has no conflict of interests; Curtis L. Meinert is involved in another trial for which Pfizer donated a different drug; Dr. Meinert owns shares of GSK stock; Constantine G. Lyketsos was involved in another trial for which Pfizer donated a different drug; he also was involved in research sponsored by Forest to study escitalopram and citalopram and Pfizer to study sertraline and donepezil; and Dr. Lyketsos served as a consultant for Organon, Eisai, GSK, Lilly, Wyeth, and Pfizer.
Role of the funding source: NIMH scientific collaborators participated on the trial's Steering Committee. Sertraline and matching placebo were provided by Pfizer, Inc., which did not otherwise participate in the design or conduct of the trial. After database lock and study unblinding, the corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. All coinvestigators had access to the raw data.
Roles of Authors and Contributors: All authors participated in data collection and revision of the paper. Initial drafting of the paper was done by DW. Data analyses were performed by LTD, CF, BKM, and CLM.